The people who could benefit most from these medications are often those least able to afford them, perpetuating a cycle in which geography, income, and health outcomes remain tightly intertwined
Long-term safety data for semaglutide comes from diabetes trials lasting approximately 2 years and the SELECT cardiovascular outcomes trial with median follow-up of about 3.3 years
Leucine is especially recognized for its powerful anabolic properties, directly stimulating muscle growth and recovery
La vitamina C no es esencial para la sntesis de carnitina
News provided by University of Colorado Anschutz Jul 29, 2026, 00:00 ET A study from the University of Colorado Anschutz found that the popular diabetes and weight loss drug reduced heavy drinking and alcohol-related harm in adults with Alcohol Use Disorder AURORA, Colo., July 29, 2026 /PRNewswire/ -- A clinical trial led by researchers at CU Anschutz has found that oral semaglutide, a medication widely used for diabetes and weight loss, reduces heavy drinking in adults with Alcohol Use Disorder (AUD)
